Introduction {#s1}
============

Idiopathic nephrotic syndrome in early life is usually steroid sensitive and carries an excellent prognosis. A minority of cases demonstrate steroid resistance, often with a focal segmental glomerulosclerosis (FSGS) pattern of injury, and evidence of heritability \[[@SFV063C1]\]. In many individuals with inherited nephrotic syndrome, the mutation is in the *NPHS2* gene which codes for podocin. Podocin is a protein located solely in the podocyte slit diaphragm \[[@SFV063C2]\], which plays an important role in maintaining the filtration barrier. Familial steroid-resistant nephrotic syndrome (SRNS) caused by autosomal recessive *NPHS2* mutations is characterized by early-onset proteinuria in childhood and resistance to immunosuppressive therapy \[[@SFV063C3]\]. Depending on when in the course of the disease a biopsy is performed, the histological lesion present may be minimal change disease (MCD) or FSGS. A number of *NPHS2* mutations have been described in both children and adults with familial and sporadic nephrotic syndrome and FSGS \[[@SFV063C4], [@SFV063C5]\].

The R229Q polymorphism (c.686G\>A; rs61747728) is a podocin variant resulting in an amino acid substitution from arginine to glutamine. It has also been associated with glomerular disease and is considered a non-neutral polymorphism \[[@SFV063C6]\]. The R229Q variant is relatively common, being present in ∼1--2% of European populations, and is associated with the development of microalbuminuria in the general population \[[@SFV063C7]\]. Cases of adult-onset FSGS have been described due to compound heterozygosity of the R229Q variant with a pathogenic podocin mutation \[[@SFV063C8]\]. Clinical assessment of patients carrying R229Q has demonstrated that individuals who are compound heterozygotes for the variant plus a pathogenic *NPHS2* mutation have a less severe phenotype with later disease onset, compared with individuals with two pathogenic mutations \[[@SFV063C9], [@SFV063C10]\]. Based on this, the current recommendation is that older children and adults should be screened for this variant of *NPHS2* \[[@SFV063C1], [@SFV063C10]\].

As part of our ongoing genetic study of childhood-onset nephrotic syndrome, we screened 19 families with early-onset SRNS for mutations in *NPHS2* and *WT1* as a prelude to whole exome sequencing. We identified three patients with disease-causing mutations in *NPHS2* and one in *WT1*. Two of the three mutations in *NPHS2* were R229Q plus a known pathogenic mutation. The three children from the two families with R229Q plus pathogenic mutations presented with SRNS and pathologic findings of MCD and FSGS between the ages of 4--14 years. Our findings illustrate the phenotypic variability associated with the *NPHS2* R229Q variant plus a pathogenic mutation, highlighting the potential for early presentation.

Materials and methods {#s2}
=====================

Clinical data {#s2a}
-------------

We selected all individuals with early disease onset (\<21 years) and a diagnosis of FSGS and/or SRNS referred to us for inclusion in our genetics of kidney disease research program. Approval for the study was granted by the Institutional Review Board (IRB) of Duke University, Durham, NC and the local IRB from the referring institutions. The clinical records of all the subjects were reviewed for age at onset, gender, family history, treatment modalities and response to therapy.

Mutation analysis {#s2b}
-----------------

Genomic DNA was extracted from whole blood samples or saliva using standard methods. Mutation analysis was performed by direct sequencing of all eight exons of *NPHS2*, and the mutation bearing exons 8 and 9 of *WT1* using exon-flanking primers. All mutations were confirmed with sequencing of the complementary strands. All sequences were analyzed using the Sequencher software package (Gene Codes Corp, Ann Arbor, MI).

Results {#s3}
=======

A total of 19 families with 31 children (14 males, 17 females) met the eligibility criteria for this study with all children presenting before 21 years of age with nephrotic-range proteinuria. Biopsy data were available in 23 children and showed an FSGS pattern of injury in 21/23 (91.3%). The other two children were reported to have MCD and diffuse mesangial sclerosis.

Mutation analysis for NPHS2 and WT1 {#s3a}
-----------------------------------

We found pathogenic mutations in 4/19 (21.1%) of the families studied, comprising an autosomal dominant *WT1* mutation (c.1432+5G\>A) in one family and *NPHS2* mutations in three families. One of the mutations in *NPHS2* is a homozygous frameshift mutation while the other two are compound heterozygous R229Q plus known pathogenic mutations. The phenotype of the four families with disease-causing mutations is shown in Table [1](#SFV063TB1){ref-type="table"}. The pedigrees in the two families with R229Q plus known pathogenic mutations are shown in Figure [1](#SFV063F1){ref-type="fig"}, while a detailed phenotypic description of these two families follows. Table 1.Clinical phenotype of four families with SRNS and mutations in *NPHS2* and *WT1*FamilyRace/CountryGeneMutationAge onset (years)HistologyAge at ESKD6647Caucasian/USA*NPHS2*c.890C\>T (A297V);\
c.386G\>A (R229Q);\
compound heterozygous4.0MCDNA34443^a^Caucasian/USA*NPHS2*c.979C\>T (L327F);\
c.386G\>A (R229Q);\
compound heterozygous13.0FSGSNA6517Caucasian/USA*NPHS2*c.467--468insA (L156fsX166);\
homozygous4.0FSGS66659Caucasian/USA*WT1*c.1432+5G\>A (IVS9+5G\>A);\
autosomal dominant1.5FSGSNA[^2][^3] Fig. 1.Family pedigrees with mutation chromatograms for the described families bearing variant R229Q plus pathogenic mutations in *NPHS2*. Squares represent males; circles represent females; solid shapes are affected individuals; crossed out shapes represent deceased family members.

Case 1 (Duke Family 34443) {#s3b}
--------------------------

A boy and his sister both presented at the age of 13 years with proteinuria. The boy was first noted to be hypertensive and edematous after a dental procedure. He had overt nephrotic syndrome and a serum creatinine of 0.9 mg/dL at presentation. Renal biopsy demonstrated an FSGS pattern of injury with mild-to-moderate interstitial fibrosis and tubular atrophy. He was unresponsive to corticosteroids, tacrolimus and rituximab therapy. One year later, he had developed significant chronic kidney disease (CKD) with an estimated glomerular filtration rate of 30 mL/min/1.73 m^2^. Following the diagnosis of her brother\'s renal disease, the sister was found on routine testing to have asymptomatic nephrotic-range proteinuria with a serum creatinine of 0.2 mg/dL. Renal biopsy also demonstrated FSGS with mild-to-moderate chronic interstitial changes. Mutation analysis in both siblings revealed compound heterozygous changes for the pathogenic *NPHS2* mutation L327F and the R229Q variant. Their parents were not available for genetic testing.

Case 2 (Duke Family 6647) {#s3c}
-------------------------

A 4-year-old girl presented with urinary frequency and urinalysis showed 2+ proteinuria. Further testing confirmed nephrotic-range proteinuria, low serum albumin and normal renal function. She was empirically treated with corticosteroids and angiotensin-converting-enzyme inhibitors but was unresponsive to therapy. She proceeded to kidney biopsy, which revealed normal light microscopic findings and diffuse podocyte foot process effacement on electron microscopy, consistent with MCD. Mutation analysis of the proband revealed a heterozygous pathogenic *NPHS2* mutation A297V and the R229Q variant. Her unaffected brother was heterozygous for the A297V mutation as was her father. Her mother was heterozygous for the R229Q variant. Neither parent nor her brother manifested disease clinically. At the last follow-up 5 years after presentation, she had normal renal function and overt proteinuria with a urine protein/creatinine ratio of 2230 mg/g.

Discussion {#s4}
==========

Mutations in *NPHS2* are a common cause of SRNS and usually present very early in life \[[@SFV063C1], [@SFV063C3]\]. Our understanding of the R229Q polymorphism in *NPHS2* continues to develop. Compound heterozygosity of R229Q, *in trans*, with a pathogenic *NPHS2* mutation is well described causing SRNS \[[@SFV063C5], [@SFV063C7], [@SFV063C10]--[@SFV063C12]\]. However, it is generally associated with a milder phenotype and a disease onset in late childhood or adulthood \[[@SFV063C6], [@SFV063C13]--[@SFV063C15]\]. Our cases confirm that this variant may be associated with disease onset in early childhood, with one individual diagnosed at age 4 years. Furthermore, the boy from Case 2 has severe disease with progressive CKD at age 14. This is consistent with a recent study by Sadowski *et al.* who investigated 1783 families with SRNS in which they identified 208 individuals with *NPHS2* mutations including 11 families (32 individuals) who were compound heterozygous for R229Q plus a pathogenic mutation \[[@SFV063C16]\]. Three of the 11 families had an early presentation, defined as \<4 years of age. Where a biopsy was performed, the histology of 148 patients with *NPHS2* mutations revealed an FSGS lesion in ∼75% of cases and in 68% of cases in the R229Q plus 1 pathogenic mutation cohort. This series contained three individuals with identical genotypes to our patients. There were two cases of R229Q plus L327F (similar to our siblings in Case 1) who presented aged 4 and 6 years and had biopsies at 16 and 19 years of age, respectively, which both showed MCD. There was one case of R229Q plus A297V podocin mutation (similar to Case 2) who presented at 4 years and had a biopsy at 6 years of age demonstrating FSGS. These findings of similar ages of onset with similar mutations are consistent with a genotype--phenotype correlation within combinations of variant R229Q plus pathogenic podocin mutations.

The influence of the R229Q variant on the development of nephrotic syndrome is complex. Genotype--phenotype correlations have demonstrated that R229Q heterozygotes generally do not manifest disease, as demonstrated in family 6647. Homozygosity for R229Q is relatively common, estimated to occur at a frequency of 1/1000 in European populations at a minor allele frequency of 2.6% in this study \[[@SFV063C11]\], yet inherited SRNS/FSGS is a rare disease. It may be present in unaffected control individuals, and most R229Q homozygotes do not have clinical disease. However, it is enriched in patients with SRNS, suggesting that it may have a modifier effect on another pathogenic gene \[[@SFV063C10], [@SFV063C17]\]. Machuca *et al.* sequenced all exons of *NPHS1, PLCE1, TRPC6* and *CD2AP* in eight individuals with SRNS who were R229Q homozygous but did not find an additional mutation \[[@SFV063C10]\]. However, there are many other risk genes, some likely undiscovered, which may harbor potentially modifiable variants. This is reflected by another report of SRNS where the proband had a *PAX2* mutation, known to cause renal coloboma syndrome \[[@SFV063C18]\], with R229Q homozygosity, but other family members without disease manifestations were homozygous for R229Q alone \[[@SFV063C17]\].

A recent study provided insight into the mechanisms by which the R229Q variant plus a pathogenic mutation may cause disease. In a study by Tory *et al.*, it was shown that the R229Q variant only leads to a SRNS/FSGS phenotype when associated with certain *NPHS2* mutations, specifically in exons 7 and 8 of the gene causing substitutions in C-terminal podocin \[[@SFV063C9]\]. Their series of experiments demonstrated that the pathogenicity of the R229Q plus a *NPHS2* mutation is probably due to dominant negative effect of the mutation on R229Q variant podocin through altered heterodimerization and mislocalization of the protein. Clinical assessment of patients carrying R229Q has demonstrated that individuals who are compound heterozygotes for the variant plus a pathogenic *NPHS2* mutation have a less severe phenotype with later disease onset, compared with individuals with two pathogenic mutations \[[@SFV063C10]\].

The study by Tory *et al.* also adds to the complexity associated with compound heterozygosity of R229Q variant plus 1 pathogenic mutation by showing incomplete penetrance in parents of affected offspring \[[@SFV063C9]\]. In total, six of these adults (representing 4.7% of the parents; aged 42--62 years) were found to also be compound heterozygotes for R229Q plus 1 pathogenic mutation but did not manifest a disease phenotype. This study also confirmed the crucial role of the *trans*-associated mutation in determining the pathogenicity of variant R229Q. Mutations in exons 7 and 8 were over-represented in individuals carrying the R229Q plus pathogenic mutations that manifested disease. The authors demonstrated in human podocyte cell lines that R229Q podocin localized correctly to the plasma membrane when co-expressed with wild-type podocin but was retained in the cytoplasm when co-expressed with podocin harboring a pathogenic exon 7 or 8 mutation. This led to altered heterodimerization of the podocin protein. Moreover, Tsukaguchi *et al*. has demonstrated *in vitro*, decreased nephrin binding to R229Q variant podocin \[[@SFV063C8]\]. In our patients, the pathogenic mutations present with R229Q were L327F in Case 1 and A297V in Case 2, both in exon 8. Both variants were found to be pathogenic in the study by Tory *et al.* \[[@SFV063C9]\]. Additional evidence that these variants are the cause of the disease in these three individuals are as follows: (i) the variants segregate perfectly with the disease in the first family and (ii) both siblings in the second family carried the same variants.

The cases we report highlight the variability of the phenotype seen with the *NPHS2* R229Q variant plus known pathogenic mutations. Individuals may present early and with aggressive disease.
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[^1]: Deceased.

[^2]: ESKD, end stage kidney disease; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; NA, not applicable.

[^3]: ^a^Both siblings in this family had an identical mutation profile and age of onset. The affected families 6647 and 34443 were compound heterozygotes for R229Q plus the stated pathogenic mutation.
